According to the 2021 European Society of Cardiology (ESC) guidelines for HF, empagliflozin, along with other SGLT2 inhibitors, is in Class I recommendations for patients with HFrEF, T2DM and HF, T2DM with high-risk CV disease, and T2DM with HFrEF [22]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.